Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 17,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elevate Clear all
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 30, 2026, 7:53 PM EDT
Withdrawn Not applicable Interventional

Remote Ischemic Conditioning in Traumatic Brain Injury

NCT03899532
View directory record Official record
Conditions
Traumatic Brain Injury, Brain Injuries, Brain Trauma, Brain Injuries, Traumatic
Interventions
Remote Ischemic Conditioning, No-Remote Ischemic Conditioning
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1 Interventional Results available

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

NCT01206465
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pralatrexate, fluorouracil, laboratory biomarker analysis, DNA analysis, high performance liquid chromatography, polymerase chain reaction, nucleic acid sequencing, pharmacological study, pharmacogenomic studies, polymorphism analysis
Drug · Other · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Warm-up on Immune Response to Exercise

NCT04868136
View directory record Official record
Conditions
Physiological and Psychological Responses to Exercise
Interventions
Exercise
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 30, 2026, 7:53 PM EDT
Withdrawn Phase 2 Interventional

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

NCT04044209
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions
AG-120, Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 30, 2026, 7:53 PM EDT
Terminated Phase 1 Interventional Results available

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564
View directory record Official record
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 30, 2026, 7:53 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Reducing Arterial Inflammation Using Eplerenone and Statins in HIV

NCT07892664
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD), Arterial Inflammation, Heart Disease
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

NCT06735599
View directory record Official record
Conditions
Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure, Male, Female, Adult, Cognition, Endothelial Function (Reactive Hyperemia), Oxidative Stress, Diet, Overweight, Body Composition Measurement, Gut Microbiome, Arterial Stiffness, Caucasian Whites, Inflammation, Microvascular Function
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

NCT01434602
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Anaplastic Glioma
Interventions
everolimus, sorafenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 30, 2026, 7:53 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

NCT01880437
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
Interventions
cytarabine, vismodegib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Stanford, California • Ann Arbor, Michigan • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 30, 2026, 7:53 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of GeoHAI Implementation

NCT05612672
View directory record Official record
Conditions
Clostridioides Difficile Infection, Healthcare Associated Infection
Interventions
GeoHAI
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases

NCT00328575
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Intensity-Modulated Radiotherapy (IMRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

NCT05603312
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AAV-GAD Low Dose, AAV-GAD High Dose, Sham Surgery
Genetic · Procedure
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
25 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
New Haven, Connecticut • West Bloomfield, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 7:53 PM EDT
Completed No phase listed Observational

Health Outcomes of Parents With Cystic Fibrosis

NCT05829694
View directory record Official record
Conditions
Cystic Fibrosis, Parenthood Status
Interventions
Parental Status
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 7:53 PM EDT
Active, not recruiting Early Phase 1 Interventional

Itraconazole to Prevent Recurrent Barrett's Esophagus

NCT05609253
View directory record Official record
Conditions
Barrett Oesophagitis With Dysplasia
Interventions
Itraconazole in capsule form, Itraconazole in solution form
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Not applicable Interventional Results available

Suicide Safety Planning Group Treatment: "Project Life Force"

NCT02525575
View directory record Official record
Conditions
Suicide
Interventions
Project Life Force Group Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 30, 2026, 7:53 PM EDT
Withdrawn Phase 1Phase 2 Interventional

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

NCT05895201
View directory record Official record
Conditions
Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Interventions
Sitagliptin, Bortezomib, Cyclophosphamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 30, 2026, 7:53 PM EDT
Active, not recruiting Not applicable Interventional

The Smart Pump Study

NCT04465201
View directory record Official record
Conditions
Cardiac Output
Interventions
Impella CP with Smart Assist (Circulatory Support System)
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
New Orleans, Louisiana • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Dose-response of Coordination Training for Older Adults.

NCT03629730
View directory record Official record
Conditions
Mobility Limitation
Interventions
Coordination training
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
70 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 30, 2026, 7:53 PM EDT
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

NCT02064036
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Stereotactic Radiosurgical Boost, Casodex, Leuprolide
Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 7:53 PM EDT